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ttp://dx.doi.org/10.1016/j.ajpath.2013.05.005Amyloid-b (Ab) peptides, starting with pyroglutamate at the third residue (pyroGlu-3 Ab), are a major
species deposited in the brain of Alzheimer disease (AD) patients. Recent studies suggest that this
isoform shows higher toxicity and amyloidogenecity when compared to full-length Ab peptides. Here,
we report the ﬁrst comprehensive and comparative IHC evaluation of pyroGlu-3 Ab deposition in
humans and animal models. PyroGlu-3 Ab immunoreactivity (IR) is abundant in plaques and cerebral
amyloid angiopathy of AD and Down syndrome patients, colocalizing with general Ab IR. PyroGlu-3 Ab
is further present in two nontransgenic mammalian models of cerebral amyloidosis, Caribbean vervets,
and beagle canines. In addition, pyroGlu-3 Ab deposition was analyzed in 12 different AD-like trans-
genic mouse models. In contrast to humans, all transgenic models showed general Ab deposition
preceding pyroGlu-3 Ab deposition. The ﬁndings varied greatly among the mouse models concerning
age of onset and cortical brain region. In summary, pyroGlu-3 Ab is a major species of b-amyloid
deposited early in diffuse and focal plaques and cerebral amyloid angiopathy in humans and nonhuman
primates, whereas it is deposited later in a subset of focal and vascular amyloid in AD-like transgenic
mouse models. Given the proposed decisive role of pyroGlu-3 Ab peptides for the development of
human AD pathology, this study provides insights into the usage of animal models in AD studies.
(Am J Pathol 2013, 183: 369e381; http://dx.doi.org/10.1016/j.ajpath.2013.05.005)Funded in part by the NIH/National Institute on Aging grants R01
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serve on the scientiﬁc advisory board of Probiodrug.Alzheimer disease (AD) is themost common form of dementia,
predicted to affect approximately 42 million people worldwide
in the year 2020.1 The two prominent histopathological hall-
marks of AD are extracellular neuritic plaques composed of
aggregated amyloid-b protein (Ab) and intracellular neuroﬁ-
brillary tangles comprising hyperphosphorylated tau.2,3 Ab is
formed via the amyloidogenic pathway in which the amyloid
precursor protein (APP) is liberated by two sequential endo-
peptidase cleavages (b- and g-secretase).4 Besides a marked
C-terminal heterogeneity of Ab peptides represented by the
isoforms Ab40 and Ab42, N-terminal variants are also
frequently found, eg, pyroGlu-3 Ab and pyroGlu-11 Ab.5stigative Pathology.
.N-terminally truncated and modiﬁed Ab species have
been shown to be a major component of Ab deposited in
plaques and vessels of AD and Down syndrome (DS)
patients.6e9 Current hypotheses suggest that pyroGlu-3 Ab
Frost et almay play an early and seminal role in the oligomerization
and seeding of Ab in familial AD (FAD) and sporadic
AD.10e12 PyroGlu-3 Ab is formed by cyclization of glutamate
residues 3 or 11 by glutaminyl cyclase (QC).13 An N-terminal
truncation of Ab precedes formation of pyroglutamic acid.
Such post-translationally modiﬁed species have been shown to
be highly toxic to neuronal and glial cultures.14 When
compared to unmodiﬁed Ab, pyroGlu-3 Ab has a higher
aggregation propensity and stability, and exhibits increased
potential to interfere with hippocampal LTP.15e17 Inhibition of
QC has been shown to prevent pyroGlu-3 Ab formation
in vitro18 and in vivo.19,20 Accordingly, QC inhibitors are
currently in development as a novel pharmacological approach
to treat and/or prevent AD.20
With the advent of numerous preclinical models, it is now
possible to mimic at least some of the pathological hall-
marks of AD for characterization and testing of potential
treatments. With regard to the established role of pyroGlu-3
Ab in AD pathology represented by neuron loss and
cognitive decline,12,21,22 a detailed characterization of
pyroGlu-3 Ab distribution of available transgenic (tg) and
nontransgenic models and their comparison to human
pathology is urgently needed. In this regard, recent research
has focused only on select models.23e26
Here, we completed detailed IHC analyses in human AD,
nondemented aged controls (AC), and DS brains, as well as
in the Caribbean vervet,27 aged beagle canines,28 and 12
AD-like tg mouse strains. Our results support the early
deposition of pyroGlu-3 Ab along with general Ab in
humans, nonhuman primates, and canines, in contrast to
later deposition in AD-like tg mouse models, underlining
differences in plaque pathology between nontransgenic/
nonrodent and transgenic murine model systems.
Materials and Methods
Human Subjects
Brain tissue from 12 AD (average, 84  7 years), 10 AC
(average, 71 12 years), and 2 DS (46 and 55 years) subjects
were collected postmortem at the time of autopsy, having
obtained prior consent from the next of kin, and following
protocols approved by the Partners Human Research Com-
mittee at Brigham andWomen’s Hospital (Boston,MA). Brain
tissue from 1 DS subject (47 years) was generously provided
for a previous study by Dr. Krystyna Wisniewski (deceased
2008; Institute for Basic Research in Developmental Disabil-
ities, Staten Island, NY). Human subject information including
age, sex, brain region examined (frontal, occipital, parietal,
temporal, temporal/hippocampal), length of tissue ﬁxation,
and postmortem interval, as well as semiquantitative staining
results for this study can be found summarized in Table 1.
Animal Models
Archived ﬁxed brain tissues or sections were obtained from
22 aged Caribbean vervets (age 13 to 32 years; Behavioral370Science Foundation, Basseterre, St. Kitts),27 three aged
beagle canines (10 to 14 years; University of California,
Irvine),28 and 12 AD-like tg mouse strains including J20 on
C57BL/629 and B6D2F130 backgrounds, J20;C3/,31
mThy-1-hAPP751,32 Tg2576,33 and Tg2576/CCL2þ/þ,34
TgSwDI,35 TgCRND8,36 3xTg-AD,37 5xFAD,38 PSAPP,39
and APP/PS1DE9.40 Speciﬁc mutations used to generate
the mouse models are illustrated in Table 2.
Tissue Preparation
Human cortical and hippocampal brain blocks were ﬁxed in
10% neutral buffered formalin for 2 hours (brief ﬁxation)
with the exception of one DS brain that was ﬁxed for
multiple years (summarized in Table 1). Archived, formalin-
ﬁxed nonhuman primate brains were blocked into nine brain
regions (rostrocaudal). Tissue blocks were processed for
parafﬁn embedding and then sectioned at 10 mm for IHC
analysis. Canines were euthanized at the University of
California, Irvine, via sodium pentobarbital overdose, their
brains were removed, and the left hemisphere was ﬁxed in
4% paraformaldehyde for months, blocked, processed for
parafﬁn embedding, and then sectioned at 10 mm. Mice
were anesthetized via CO2 inhalation, perfused with 20 mL
of ice-cold saline followed by brain removal. Hemibrains
were ﬁxed in 10% formalin or 4% paraformaldehyde for 2
to 24 hours before being processed for parafﬁn embedding
and then sectioned at 10 mm. All use of mice at Brigham and
Women’s Hospital was approved by the Harvard Medical
Area Standing Committee on Animals and was in compli-
ance with all state and federal regulations.
PyroGlu-3 Ab Antibody Characterization
Surface Plasmon Resonance
PyroGlu-3 Abespeciﬁc clone 24 was characterized by
surface plasmon resonance. Brieﬂy, the analyses were per-
formed on a Biacore 3000 (GE Healthcare, Chalfont St Giles,
UK). A CM5 chip was covalently conjugated with 100
response units (RU) of test peptides on ﬂow cells (Fc) 2, 3,
and 4 (Supplemental Table S1). Fc 1 was prepared for blank
subtraction. Clone 24 was diluted in running buffer HEPES-
buffered saline, 3 mmol/L EDTA, 0.005% v/v surfactant P20
(HBS-EP) at a concentration of 25 mg/mL. First, a basal
signal was determined with HBS-EP, followed by 180
seconds of application of antibody dilution, to determine
association of antibody to antigen. Pure HBS-EP was then
injected again for another 180 seconds to observe the
dissociation of the corresponding antibody. Next, the afﬁnity
constants of different Ab peptides to pyroGlu-3 Abespeciﬁc
antibody clone 24 were determined (Supplemental Table S2).
A CM5 chip was covalently conjugated with about 15,000
response units (RU) of an anti-mouse antibody on Fc 4. Fc 3
was prepared for blank subtraction. Clone 24 was diluted in
running buffer HBS-EP at a concentration of 25 mg/mL and
immobilized by the anti-mouse antibody on Fc 4 with aboutajp.amjpathol.org - The American Journal of Pathology
Table 1 Examination Summary for Human Subjects
Identiﬁer Age (years) Sex Fixation* Brain region examined R1282 IR PyroGlu-3 IR PMI (hours)
Control
AC-1 87 F Brief P þ þ
T/HC  
AC-2 72 F Brief T  
HC  
AC-3 90 M Brief FR þ þ 17
HC þ þ
AC-4 60 F Brief O þ þ 11
HC þ þ
AC-5 64 M Brief FR þ þ 9.5
HC þ þ
AC-6 76 F Brief HC   17
AC-7 53 M Brief HC   9
AC-8 70 M Brief FR þ þ 17
AC-9 74 M Brief FR þ þ
AC-10 60 F Brief FR þ þ 35
Alzheimer disease
AD-1 82 F Brief FR þ þ 15.75
HC þ þ
AD-2 79 F Brief FR þ þ 13
HC þ þ
AD-3 91 F Brief FR þ þ 3.75
HC þ þ
AD-4 71 M Brief FR þ þ 36
HC þ þ
AD-5 84 F Brief FR þ þ
T þ þ
AD-6 92 F Brief HC þ þ 7.75
AD-7 78 M Brief O þ þ 18
HC þ þ
AD-8 96 F Brief O þ þ 21
HC þ þ
AD-9 78 M Brief FR þ þ
T/HC þ þ
AD-10 88 F Brief P þ þ <24
HC þ þ
AD-11 84 F Brief FR þ þ 16.5
HC þ þ
AD-12 88 F Brief FR þ þ
HC þ þ
Down syndrome
DS-1 47 M Long FR þ þ 34
T/HC þ þ
DS-2 55 M Brief FR þ þ
T þ þ
DS-3 46 F Brief FR þ þ 18
T/HC þ þ
Semiquantitative staining results are shown for general Ab (R1282) and pyroGlu-3 Ab.
*Length of tissue ﬁxation in formalin (brief: 2 hours; long: multiyear).
F, female; M, male; FR, frontal; O, occipital; P, parietal; PMI, postmortem interval; T, temporal; T/HC, temporal/hippocampal.
pGlu-Ab in Humans and Animal Models1000 to 2000 RU. The test peptides (Supplemental Table S2)
were diluted at concentrations ranging from 2 nmol/L to 500
nmol/L. First, a basal signal was determined with HBS-EP,
followed by 240 seconds of application of peptide dilution,
to determine association of antigen to antibody. PureThe American Journal of Pathology - ajp.amjpathol.orgHBS-EP was then injected again for another 1200 seconds to
observe the dissociation of the corresponding antibody. This
cycle was performed for every concentration of the test
peptides. Interactions of the test peptides with the anti-mouse
capture antibody were not observed (not shown). Data were371
Table 2 Semiquantitative (0 to 4þ) Scoring of General Ab (R1282) Immunoreactive Plaques and PyroGlu-3 AbePositive Plaques in 12 AD-
Like tg Mouse Models Examined
Mouse model Reference Promoter Age (months) R1282 IR PyroGlu-3 IR 6E10 IR
J20 C57BL/6 APPK670N/M671L,V717F 29 PDGF 8 (n Z 2) 2þ 1þ 2þ
12 (n Z 6) 2.5þ 2.67þ 3þ
17 (n Z 4) 2.75þ 2.25þ 2.75þ
30 (n Z 2) 4þ 3þ 3þ
J20 B6D2F1 APPK670N/M671L,V717F 30 PDGF 6 (n Z 4) 2.5þ 1.75þ 1.75þ
9 (n Z 4) 2þ 0.75þ 1.5þ
16 (n Z 5) 4þ 3þ 3þ
24 (n Z 2) 4þ 3þ 3þ
J20;C3/ APPK670N/M671L,V717F
Complement factor C3 deﬁcient
31 PDGF 8 (n Z 6) 2.17þ 1.5þ 2.17þ
12 (n Z 10) 2.8þ 1.9þ 3þ
17 (n Z 5) 4þ 3þ 3þ
hAPP751 APPK670N/M671L,V717I 32 mThy-1 14 (n Z 2) 4þ 4þ 3þ
Tg2576 Tg2576/CCL2
APPK670N/M671L,V717I
33, 34 Hamster PrP (APP)
hGFAP (CCL2)
14 (n Z 4) 2þ 1.25þ 2þ
14 (n Z 4) 2.75þ 1.75þ 2.5þ
TgSwDI APPK670N/M671L E693Q, D694N 35 mThy-1 3 (n Z 4) 1.5þ 0.75þ 2.25þ
6 (n Z 2) 3þ 2þ 1.5þ
12 (n Z 4) 3þ 1.5þ 3þ
24 (n Z 4) 4þ 3þ 3þ
TgCRND8 APPK670N/M671L/V717F 36 Hamster PrP 83 days (n Z 3) 2þ 0.5þ 2þ
<300 days (n Z 2) 4þ 3þ 3þ
3xTg-AD APPK670N/M671L,
PS1M146V ,TauP301L
37 mThy-1 (APP, Tau)
PS1 KI
14 (n Z 8) 1þ 0.5þ 1þ
22 (n Z 4) 2þ 1þ 2þ
25 (n Z 3) 3þ 1.5þ 3þ
5xFAD APPK670N/M671L, I716V, V717I
PS1M146L, L286V
38 mThy-1 1.5 (n Z 1) 1þ 0 NE
2 (n Z 2) 2.5þ 0 NE
4 (n Z 1) 4þ 2þ NE
6 (n Z 2) 4þ 3þ NE
9 (n Z 1) 4þ 3þ NE
12 (n Z 12) 4þ 4þ NE
PSAPP APPK670N/M671Lx PS1M146L 39 Hamster PrP (APP)
PDGF (PS1)
4 (n Z 6) 2þ 0 NE
18 (n Z 4) 4þ 4þ 3þ
APP/PS1DE9 APPK595N/M596L
PS1 deletion of exon 9
40 mPrP (APP, PS1) 6 (n Z 2) 2þ 1þ 2þ
14 (n Z 5) 4þ 3þ 3þ
24 (n Z 4) 4þ 4þ 3þ
General Ab was conﬁrmed with anti-Ab mAb 6E10. Plaque scoring of each group is given as a mean value calculated from the sum of individual scores
divided by the number of animals per group. Scoring key: 1þZ 1 to 5 plaques; 2þZ 6 to 10 plaques, 3þZ 11 to 100 plaques; 4þZ 101 or more plaques.
NE, not examined.
Frost et alevaluated by either the 1:1 Langmuir binding ﬁt model or the
steady-state model for calculating the dissociation constants.
Dot Blot Assay
To further conﬁrm the speciﬁcity of anti-pyroGlu-3 mono-
clonal antibody (mAb) (clone 24), a dot blot assay was
performed. The following Ab peptides: 1-7, 3-9, pE3-9, 3-
13, 1-15, 3-40, pE3-40, and 1-40 were loaded onto a 0.2-mm
nitrocellulose membrane (Bio-Rad, Hercules, CA) at 1000,
100, 10, and 1 ng. Bovine serum albumin (Sigma-Aldrich,
St. Louis, MO) and PBS were loaded as negative controls.
Peptides or PBS were allowed to air dry for 30 minutes at
room temperature. Following drying, membranes were
blocked for 1 hour at room temperature in 10% Odyssey
Blocking Buffer (LI-COR Biosciences, Lincoln, NE) and372probed with either clone 24 at 0.54 mg/mL (Supplemental
Figure S1) or 6E10 at 0.5 mg/mL (as a positive control;
data not shown) overnight at 4C. The following day,
membranes were washed three times in PBS with 0.05%
Tween 20 (PBS-T), incubated with the appropriate
secondary antibody for 2 hours at room temperature, and
visualized using a Li-COR scanner (LI-COR Biosciences).
Antibody Adsorption
In addition, the speciﬁcity of clone 24 was conﬁrmed by
IHC by preincubation of clone 24 with pE3-40 Ab synthetic
peptide at a concentration of 15 mg of peptide/1 mg of
antibody. Clone 24 was diluted to a ﬁnal concentration of 1
mg/mL, and 15 mg of synthetic pE3-40 Ab peptide was
added per milliliter of diluted antibody solution. Theajp.amjpathol.org - The American Journal of Pathology
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shaking at 4C. The following day, the adsorbed clone 24
antibody was applied to cortical brain sections from
a human AD case, aged nonhuman primate, aged beagle
canine, and APPswe/PS1DE9 brain sections, all with known
amyloid pathology. Adjacent serial sections from each case
were also immunostained, in parallel, with preadsorbed
clone 24 and 82E1 mAb (IBL International, Hamburg,
Germany), which is speciﬁc for Ab starting at Asp 1, at
1 mg/mL. Immunoreactivity was visualized using a Vector-
Elite horseradish peroxidase ABC kit (Vector Laboratories,
Burlingame, CA) and 3,30-diaminobenzidine (DAB) as
chromogen (Sigma-Aldrich).
Immunohistochemistry
Serial sections (10 mm) were cut for peroxidase IHC and
double immunoﬂuorescence labeling. In brief, sections were
deparafﬁnized in two changes of Histo-Clear (National
Diagnostics, Atlanta, GA) and rehydrated in graded ethanol
solutions. Endogenous peroxidase activity was quenched
with 0.3% H2O2 in methanol for 10 minutes. All parafﬁn
sections were pretreated with 88% formic acid for 8 minutes
to increase recognition of antigen binding sites. Sections
were subsequently washed with water for 10 minutes and
incubated with primary antibody overnight at 4C. After
incubation for 30 minutes at room temperature with a bio-
tinylated secondary antibody (Vector Laboratories) IR was
visualized with the VectorElite horseradish peroxidase ABC
kit (Vector Laboratories) and DAB (Sigma-Aldrich) as
chromogen. When using mouse mAbs on mouse brain
sections, a Mouse on Mouse (M.O.M.) kit (Vector Labo-
ratories) was used to inhibit nonspeciﬁc background stain-
ing. General Ab deposition was analyzed using two
antibodies, R1282 and 6E10. R1282 (dilution 1:1000),
a general Ab rabbit polyclonal antibody [a gift from Dennis
J. Selkoe (Center for Neurologic Diseases, Boston, MA)],
was raised against synthetic Ab1-40 peptide and recognizes
multiple epitopes and conformations. The mouse mAb 6E10
(dilution 1:1000; Covance, Dedham, MA) is reactive to
Ab1-16, speciﬁcally recognizing an epitope within residues
3 to 8 of Ab. An antiepyroGlu-3 Ab mAb [clone 24,
dilution 1:1000; Probiodrug, Halle (Saale), Germany] was
used for comparison with general Ab. Furthermore, an
Ab42 polyclonal antibody, QCB42 (dilution 1:100; Bio-
Source, Camarillo, CA) and an Asp-1 Abespeciﬁc mAb,
82E1 (1 mg/mL; IBL International) were used in some
tissues. Primary antibody was omitted from sections as
a negative control, which consistently yielded negative
results (data not shown).
Immunoﬂuorescence
To assess colocalization of general Ab to pyroGlu-3 Ab,
double immunoﬂuorescence labeling was performed using
R1282 and antiepyroGlu-3 Ab antibodies in mouse sagittalThe American Journal of Pathology - ajp.amjpathol.orgbrain sections, coronal human brain sections, and nonhuman
primate brain sections. Parafﬁn sections were prepared as
noted above, including pretreatment with 88% formic acid
for 8 minutes with incubation of both primary antibodies at
4C overnight. Thereafter, sections were incubated for 2
hours at room temperature with goat anti-mouse AlexaFluor
488 (dilution 1:200; Invitrogen, Carlsbad, CA) and goat
anti-rabbit Rhodamine Red-X (dilution 1:200; Invitrogen) as
secondary antibodies for visualization. Finally, sections
were treated with 0.3% Sudan black (Sigma-Aldrich) in
70% ethanol to quench autoﬂuorescence. Controls to
exclude nonspeciﬁc binding or cross reactivity included
omission of both primary antibodies or both ﬂuorescent
secondary antibodies. These measures consistently yielded
negative results (data not shown). In addition, separate
sections were incubated with one primary and a mixture of
both secondary antibodies, or both primary antibodies and
one secondary antibody. In both cases, IR was detected for
only a single primary antibody.
Results
N-Terminally Truncated and PyroGlu-3eModiﬁed Ab
Species in AD, Down Syndrome, and Nondemented
Aged Control Brains
Cortical brain sections were stained with polyclonal anti-
body R1282 (general Ab) (Figure 1, AeC) and a mAb
detecting pyroGlu-3 Ab (Figure 1, DeF) to assess Ab
deposition in 12 AD cases, 3 DS cases, and 10 AC cases.
The pyroGlu-3 Abespeciﬁc antibody used here is selective
for pyroGlu-3 Ab, showing <1% cross-reactivity to other
Ab peptides or pyroGlu peptides as determined by surface
plasmon resonance and dot blot analysis (Supplemental
Tables S1 and S2, and Supplemental Figure S1). Further-
more, preadsorption of clone 24 with pyroGlu-3-40 Ab
peptide strongly reduced staining in brain parenchyma in the
different species (Supplemental Figure S2). Staining was
performed on adjacent serial sections to compare R1282 IR
to pyroGlu-3 Ab IR. A summary of human staining results
is provided in Table 1. As an example, general Ab and
pyroGlu-3 Ab deposition is shown in the frontal cortices of
a 78-year-old male AD patient (Figure 1, A and D), a 47-
year-old male DS individual (Figure 1, B and E), and
a 74-year-old male AC (Figure 1, C and F). IHC analysis
revealed pyroGlu-3 Ab to be present in diffuse and focal Ab
plaques in 12 of 12 AD cases, 3 of 3 DS cases, and the 7
plaque-bearing of 10 AC cases. These results indicated that
virtually all plaques that displayed R1282 IR in AD and AC
also contained varying levels of pyroGlu-3 Ab IR.
Furthermore, pyroGlu-3 Ab IR was also noted in paren-
chymal blood vessels of frontal cortex in AD, DS, and AC
cases. In contrast to AD and AC, DS cases showed
increased pyroGlu-3 Ab IR (Figure 1E) compared to R1282
IR (Figure 1B) in diffuse and compacted plaques and
cerebral amyloid angiopathy (CAA). However, staining373
Figure 1 N-terminaletruncated and pyroGlu-3emodiﬁed Ab species
were colocalized in AD (A, D, and GeI), DS (B and E), and AC (C and F)
frontal cortex. Immunohistochemical staining was performed on adjacent
serial parafﬁn sections with antibodies R1282 (AeC) and antiepyroGlu-3
Ab (DeF), respectively. Double immunoﬂuorescence labeling of R1282 (G)
and pyroGlu-3 Ab (H) shows abundant colocalization (I). Scale bars: 100
mm (F and I).
Frost et alwith a C-terminalespeciﬁc Ab42 antibody showed a 1:1
ratio of pyroGlu-3 Ab to full-length Ab (data not shown).
To further ensure that pyroGlu-3 Ab colocalized with
general Ab deposition, double immunoﬂuorescence staining
was performed. Immunoﬂuorescence using R1282 and
pyroGlu-3 Ab antibodies in a subset of the 12 AD cases
conﬁrmed results observed with peroxidase staining, indi-
cating that pyroGlu-3 Ab deposition was present in all
cortical plaques and CAA along with general Ab deposition
(Figure 1, GeI). In addition, pyroGlu-3 Ab (detected by
clone 24) and Asp-1 Ab (detected by antibody 82E1)
showed an almost complete overlap of immunoreactivities
in human AD brain (Supplemental Figure S2).Figure 2 Immunohistochemical analysis of aged Caribbean vervets in
formalin-ﬁxed, parafﬁn-embedded frontal cortex sections comparing R1282
IR (AeC) and pyroGlu-3 Ab IR (DeF) on adjacent serial sections. Both
R1282 (A) and pyroGlu-3 Ab (D) deposition begins in the parenchymal
vasculature, as shown in a 17-year-old monkey. With aging, cerebral
pyroGlu-3 Ab is ﬁrst found in diffuse deposits of brieﬂy ﬁxed brains (E) and
also in plaques and CAA of long-term ﬁxed brains (F); however, there,
pyroGlu-3 Ab is only detected in a subset of R1282-positive plaques (C).
GeI: Double immunoﬂuorescence labeling with R1282 (red; G), pyroGlu-3
Ab (green; H), and merged (I) reveal striking colocalization of N-terminally
truncated and pyroGlu-3emodiﬁed Ab species in plaques and CAA in the
frontal cortex of a 24-year-old vervet. Scale bar Z 100 mm (I).In Caribbean Vervets and Aged Beagle Canines,
PyroGlu-3 Ab Is Initially Deposited in Vascular Amyloid
and, Subsequently, in Cortical Plaques
We next examined the presence of pyroGlu-3 Ab in two
species known to sporadically develop cerebral amyloidosis,
the Caribbean vervet, a nonhuman primate model that has
been previously shown to accumulate cerebral Ab in pla-
ques and CAA with aging27 and beagle canines.28 Deposi-
tion started around 17 years in vervets and increased with
age. Of importance was the ﬁnding that IHC staining of
pyroGlu-3 Ab was sensitive for ﬁxation time due to a lack
of diffuse pyroGlu-3 Ab deposits in long-term ﬁxed vervet
brain. There, pyroGlu-3 Ab IR (Figure 2F) was only noted
in a subset of R1282-positive plaques (Figure 2C). By
contrast, pyroGlu-3 Ab was already present in diffuse374deposits (Figure 2E) of brieﬂy ﬁxed (2 hours) vervet brain
tissue matching R1282 IR (Figure 2B). Vascular amyloid
containing pyroGlu-3 Ab was shown to precede plaque
deposition, starting at the age of 13 years, and was abundant
in parenchymal vessels by 17 years (Figure 2D), and colo-
calized strongly with R1282 IR (Figure 2A). Of the 22
vervets characterized in this study, pyroGlu-3 Ab was
present in frontal cortical plaques of 7 of 22 vervets (age
>15 years) and in the blood vessels of 8 of 22 vervets (age
>13 years). Double immunoﬂuorescence staining conﬁrmed
DAB IHC visualization; however, in contrast to peroxidase
single labeling, pyroGlu-3 Ab deposition (Figure 2H) was at
a 1:1 ratio (Figure 2I) with general Ab (Figure 2G) in pla-
ques and CAA.
Moreover, we conducted IHC analyses with long-term
ﬁxed prefrontal cortex from three aged beagle canines. The
youngest canine (age 10 years) had only diffuse Ab42-
positive plaques in prefrontal cortex (Figure 3A) with no
pyroGlu-3 Ab IR (Figure 3D). By contrast, Ab42-positive
diffuse and compacted plaques, as well as CAA, were
detected in the two older canines (12 years) (Figure 3B) and
(14 years) (Figure 3C). Ab42 IR across the entire section
was greatest in the oldest canine (14 years), suggesting that
plaque deposition in canines increases with age. PyroGlu-3
Ab deposition was also detected in the two oldest canines
(12 and 14 years) (Figure 3, E and F), with higher levels in
the older animal. Most of the pyroGlu-3 Ab IR was seen in
blood vessels and colocalized with Ab42 IR. To a lesser
extent, pyroGlu-3 Ab IR was observed in a few compacted
Ab42-positive plaques at 12 and 14 years of age, respec-
tively (Figure 3F). PyroGlu-3 Ab IR and Asp-1 Ab IRajp.amjpathol.org - The American Journal of Pathology
pGlu-Ab in Humans and Animal Modelsstrongly overlapped in both vervet and canine brain, as was
observed in human brain (Supplemental Figure S2).
However, in beagle canine brain, there was somewhat less
pyroGlu-3 Ab IR compared to Asp 1 Ab IR, likely due to
the long ﬁxation time.
PyroGlu-3 Ab Accumulation Varies in AD-Like tg Mouse
Models by Age of Onset, Cortical Region, and General
Abundance
Murine models are the primary source for AD research
in vivo due to the possibility of genetic manipulation.
Consequently, a plethora of AD mouse models reﬂecting
certain aspects of human AD are now available. Therefore,
we next investigated the deposition of general and pyroGlu-
3 Ab peptides in 12 different mouse models of AD. The
different mouse models were further grouped by their AD-
related transgenes. Details on genetic mutations and semi-
quantitative analysis of general and pyroGlu-3 Ab IR in
each mouse model can be found in Table 2.
PyroGlu-3 Ab Deposition in tg Mice Based on
Expression of Different APP Mutants
Among the mice examined, Tg2576, J20, TgCRND8, and
TgSwDI were generated on the basis of the expression of
human familial APP mutations.
First, we characterized the widely used AD-like tg mouse
model, Tg2576, based on expressing the Swedish mutation.
At 14 months of age, R1282 IR was localized in the
hippocampus, in particular along the molecular layer of the
dentate gyrus (DGm) (not shown), in the neocortex, and in
blood vessels along the pial surface (Supplemental
Figure S3C). Minute focal deposits of pyroGlu-3 Ab IR
were noted distinctly only in the DGm and subiculum (notFigure 3 Immunohistochemistry on paraformaldehyde-ﬁxed and
parafﬁn-embedded prefrontal cortex from aged beagle canines with
a C-terminalespeciﬁc Ab 42 (AeC) and pyroGlu-3 antibody (DeF) reveals
diffuse Ab42 deposits at 10 years of age (A) that are devoid of pyroGlu-3
Ab IR (D). Staining in a 12-year-old canine shows Ab42-positive blood
vessels (B) that are concomitantly immunolabeled by pyroGlu-3 Ab mAb on
an adjacent serial section (E). In the oldest canine examined in this study
(14 years), focal Ab42epositive deposits are observed (C); however, only
a subset are pyroGlu-3 Ab positive (F). Insets show the magniﬁed areas
indicated by the arrows. Scale bar Z 50 mm (F).
The American Journal of Pathology - ajp.amjpathol.orgshown). When comparing Tg2576 mice with age-matched
Tg2576/CCL2þ/þ that additionally overexpress human
monocyte chemoattractant protein (MCP-1, CCL2),34 we
observed an overt increase in general Ab diffuse and focal
deposits (Supplemental Figure S3E) and pyroGlu-3 Ab
focal deposits in the neocortex (Supplemental Figure S3F).
Next, we analyzed J20 and TgCRND8 mice possessing
both the Swedish and Indiana mutations. J20 mice show Ab
deposition starting at 6 months in the hippocampus29 that
continues to radiate out to the neocortex with aging. We
examined a temporal series of J20 mice on a hybrid back-
ground (C57BL/6  DBA/2) at 6, 9, 16, and 24 months,
as well as J20 and J20;complement factor 3-deﬁcient
(J20;C3/) mice at 8, 12, and 17 months on the C57BL/
6 background. We further sought to examine immunohis-
tochemically (IHC) whether strain background and/or C3
deﬁciency inﬂuenced pyroGlu-3 Ab deposition as previ-
ously noted for general Ab deposition.30,31 A summary of
the number of mice for each strain analyzed, as well as
semiquantitative plaque scoring for R1282 and pyroGlu-3
Ab IR, can be found in Table 2.
At all ages, and in all three J20 lines, general Ab was more
abundant than pyroGlu-3 Ab (Supplemental Figure S4,
AeF). PyroGlu-3 Ab IR was noted at modest levels exclu-
sively in the hippocampus in three of four J20 B6D2F1
hybrid mice at 6 months of age. By contrast, J20 and
J20;C3/ mice on a C57BL/6 background displayed less
pyroGlu-3 Ab IR in the hippocampus at 8 months of age
compared to hybrid mice at 6 months (Table 2). In all three
strains, pyroGlu-3 Ab deposition started as plaques in
hippocampus, increasing with age to cortical plaques, fol-
lowed by vascular deposits. In the J20 B6D2F1 mice,
pyroGlu-3 Ab IR was additionally present in the DGm at 6
months. By 9 months, J20 B6D2F1 mice displayed increased
pyroGlu-3 Ab IR in the hippocampus and the initial
appearance of cortical plaques. At 16 months, J20 hybrid
mice had moderate pyroGlu-3 Ab deposition (plaque score,
3þ) (Table 2) in the neocortex, hippocampus, and subiculum.
Parenchymal vascular amyloid was ﬁrst identiﬁed at this age.
By 24 months, diffuse pyroGlu-3 Ab IR was noted speciﬁ-
cally in the DGm. J20 and J20;C3/ on the C57BL/6
background showed a similar progression of pyroGlu-3 Ab
deposition at 12 and 17months relative to the J20 mice on the
hybrid background, with an age-dependent increase of
pyroGlu-3 Ab in the hippocampus and pyroGlu-3
Abepositive blood vessels appearing in the parenchyma at
16 months. At 17 months, in contrast to J20 on the C57BL/6
and B6D2F1 backgrounds at similar ages, J20;C3/ mice
displayed a marked increase in neocortical diffuse and focal
plaques immunolabeled with both R1282 (Supplemental
Figure S4C) and pyroGlu-3 Ab (Supplemental Figure S4F)
antibodies, respectively.
Compared to J20 mice, TgCRND8 mice showed much
earlier general Ab deposition in the neocortex and DGm
starting at 3 months; however, no pyroGlu-3 Ab deposition
was observed at this age. PyroGlu-3 Ab deposition in the375
Figure 4 General Ab (R1282) IR was compared
to pyroGlu-3 Ab IR in the hippocampus of J20 tg
mice on the C57Bl/6 background (A and B), mThy-
1-hAPP751 (C and D), TgSwDI (E and F), TgCRND8
(G and H), PSAPP (I and J), APP/PS1DE9 (K and
L), 3xTg-AD (M and N), and 5XFAD (O and P) mice
at time points of advanced general Ab and
pyroGlu-3 Ab deposition. In general, pyroGlu-3 Ab
is less abundant and colocalizes with only a subset
of R1282-positive general Ab deposits, although
the amount of pyroGlu-3 Ab varied by model. Scale
bar Z 200 mm (P).
Figure 5 Progression of general Ab (AeC) corresponds to increases in
pyroGlu-3 Ab (DeF) in the hippocampal CA1 region in TgSwDI. At 6
months, minute amounts of general Ab (A) and even less pyroGlu-3 Ab (D)
can be detected in the CA1 region. By 12 months, both R1282 (B) and
pyroGlu-3 Ab (E) are increased in the microvasculature between the pyra-
midal neurons and in the stratum oriens. By 24 months, intense CAA is
observed with immunostaining with R1282 (C) that colocalizes almost
completely with pyroGlu-3 Ab (F). Scale bar Z 25 mm (F).
Frost et alhippocampus and cortex of TgCRND8 mice occurred later
and followed a general Ab staining pattern, although
pyroGlu-3 Ab IR was not present in all plaques. In the two
oldest mice (10 and 11 months, respectively), general Ab-
and pyroGlu-3 Abepositive focal deposits were detected in
hippocampus (Figure 4, G and H), neocortex, olfactory bulb
(Supplemental Figure S3, G and H), and thalamus. General
Ab deposits were found in all four brain regions as well as
cerebellum, and were more abundant. Interestingly,
pyroGlu-3 Ab was not noted in any of the vasculature in this
model even though general Ab vascular deposits were
observed in the parenchyma and leptomeninges with R1282
(data not shown).
Two 14-month-old mThy-1-hAPP751 tg mice bearing the
Swedish and London mutations were immunolabeled with
R1282 and the pyroGlu-3 Ab mAb on adjacent serial
sections. This APP tg strain begins depositing plaques
between 3 to 4 months of age in the neocortex, and by 5 to 7
months, plaques progress to the hippocampus, thalamus,
and olfactory bulb.32 Intense pyroGlu-3 Ab IR (Figure 4D)
colocalized with general Ab deposition (Figure 4C) in
diffuse and focal plaques throughout the entire hippocampus
at 14 months. In addition, pyroGlu-3 Ab (Supplemental
Figure S3B) followed the general Ab deposition pattern in
the neocortex (Supplemental Figure S3A) and thalamus, as
well as in leptomeningeal and parenchymal blood vessels.
Interestingly, R1282 IR in diffuse, extracellular deposits
was observed in the olfactory bulb and spinal cord;
however, no pyroGlu-3 Ab IR was observed in these two
regions (data not shown).
TgSwDI mice harboring three different APP mutations
(Swedish/Dutch/Iowa) were examined for general Ab and
pyroGlu-3 Ab deposition at 3, 6, 9, 12, and 24 months,376respectively. Detailed IHC analyses revealed that this AD-
like tg mouse had some of the earliest and most abundant
cerebral pyroGlu-3 Ab deposition, seen as vascular deposits
that increased with age. Initially, R1282 and pyroGlu-3 Ab
were both observed solely in the subiculum at 3 months
(data not shown). At 6 months of age, general Ab deposition
(mostly vascular) had radiated to the thalamus, stratum
oriens, CA1 (Figure 5A), DGm, and dentate gyrus poly-
morphic layers (DGpl), and concomitantly increased in the
subiculum. PyroGlu-3 Ab was observed in a subset of
general Ab plaques in the subiculum, thalamus, and stratum
oriens, and CA1 region (Figure 5D). At this age, general Ab
was in its early stages of deposition in the neocortex, but no
pyroGlu-3 Ab was detected. By 12 months, pyroGlu-3 Abajp.amjpathol.org - The American Journal of Pathology
Figure 6 Progression of cerebral general Ab (AeC) and pyroGlu-3 Ab
(DeF) deposition in APP/PS1DE9 mice. Mice were immunolabeled with
R1282 and pyroGlu-3 Ab antibodies at 6, 14, and 24 months, respectively.
General Ab is immunolabeled initially in the neocortex (not shown) and
hippocampus (A) at 6 months. One pyroGlu-3 Abepositive plaque could be
detected at 6 months in the hippocampus (D). By 14 months, pyroGlu-3 Ab
deposition progresses to the neocortex as focal and diffuse deposits (E)
that colocalize completely with general Ab (B). In contrast to PSAPP mice
at 18 months, robust general Ab (C) and pyroGlu-3 Ab IR is noted in
molecular layer and leptomeningeal blood vessels in the cerebellum of 24-
month-old mice. Scale bar Z 50 mm (F).
pGlu-Ab in Humans and Animal Modelsdeposition (Figure 5E) had increased in the aforementioned
regions (Figure 5B) and was found in a subset of general Ab
deposits in the hippocampal CA2 region, DGm, and
neocortex. By 24 months, pyroGlu-3 Ab (Figures 4F and
5F) and R1282 (Figures 4E and 5C) were at a near 1:1 ratio
in the hippocampus, speciﬁcally in the CA1 (Figure 5, C
and F), CA2, CA3, DGm, DGpl, stratum oriens, the thal-
amus, and neocortex (data not shown).
In summary, pyroGlu-3 Ab deposition followed the
appearance and was less abundant than plaques positive for
general Ab in APP-overexpressing models. The more
aggressive the Ab pathology, the earlier pyroGlu-3 Ab was
observed. Interestingly, two adjacent mutations within the
Ab sequence (Dutch/Iowa) were associated with very early
detection of pyroGlu-3 Ab vascular deposits in TgSwDI
mice.
PyroGlu-3 Ab in tg Mice Based on Expression of
Different APP-Variants with Presenilin Mutations
The next group of models comprised PSAPP, 5XFAD, and
APP/PS1DE9 mice. These are characterized by the
combined expression of mutated human presenilin and
human APP mutations.
The ﬁrst model in this group, PSAPP, are Tg2576 mice
possessing the Swedish APPmutation crossed to PS1M146L tg
mice. At 4 months of age, all six mice examined were devoid
of general and pyroGlu-3 Ab measured immunohis-
tochemically. When 18-month-old mice (n Z 4) were
immunolabeled with R1282 and pyroGlu-3 Ab antibodies on
adjacent serial sections, abundant general Ab (Figure 4I) and
pyroGlu-3 Ab (Figure 4J) deposits were observed throughout
the entire brain. General Ab appeared as both focal and
diffuse deposits throughout the cortex (Supplemental
Figure S5A), hippocampus, and thalamus. Vascular
amyloid was noted in the parenchyma pial surface and only in
the leptomeninges of the cerebellum in sections stained with
R1282 (Supplemental Figure S5C). As was commonly
observed in most of the AD-like tg mouse models, pyroGlu-3
Ab deposition was observed in focal deposits only,
throughout the cortex (Supplemental Figure S5D), hippo-
campus, thalamus, and olfactory bulb (Supplemental
Figure S5E), as well as in R1282-positive blood vessels in
the cerebellum (Supplemental Figure S5F), cortical paren-
chyma, and pial surface in old PSAPP mice (data not shown).
For 5XFAD mice harboring three different APP muta-
tions (Swedish/Florida/London) and two different PS1
mutations (PS1M146L, PS1L286V), cerebral Ab deposition was
detected very early, at 1.5 months of age, with several
R1282 IR plaques noted in layer V of the cortex and in
subiculum. However, no pyroGlu-3 Ab IR was detected at
this young age. There was a dramatic increase in R1282 IR
in the mice examined at 2 months of age in which general
Ab deposition was observed throughout the hippocampus,
most intensely in the subiculum, and continued to increase
in the cortex from cortical layer V; however, pyroGlu-3 AbThe American Journal of Pathology - ajp.amjpathol.orgIR was not observed. At 4 months of age, pyroGlu-3 Ab
was shown to be deposited in focal plaques throughout
cortical layer V (Supplemental Figure S3L) and the sub-
iculum, which colocalized with the cores of R1282-positive
plaques (Supplemental Figure S3K). By 6 months of age,
pyroGlu-3 Ab continued to increase throughout the entire
cortex and subiculum, and was detected in DGpl. By 9 and
12 months of age, respectively, general Ab (Figure 4O) and
pyroGlu-3 Ab (Figure 4P) were observed as focal deposits
covering the entire brain.
Finally, APP/PS1DE9 mice, harboring the Swedish APP
mutation and a deletion of exon 9 in PS1, displayed general
Ab plaque deposition (R1282 IR) in the hippocampus
(Figure 6A) at 6 months, but not in neocortex or cerebellum.
Surprisingly, pyroGlu-3 Ab was observed in a small subset
of focal plaques in the hippocampus in two of four mice, but
not elsewhere at this young age (Figure 6D). By 14 months,
general Ab-immunopositive diffuse, focal, and vascular
deposits had increased dramatically in the neocortex
(Figure 6B), hippocampus, and cerebellum. Interestingly,
APP/PS1DE9 mice at 14 months displayed pyroGlu-3 Ab
IR in diffuse and focal deposits in the neocortex (Figure 6E)
as well as in the parenchymal blood vessels and focal
deposits in the hippocampus and cerebellum. By 24 months,
abundant general Ab IR was noted in the hippocampus
(Figure 4K), neocortex, and cerebellum. Most compacted
plaques in the hippocampus (Figure 4L) and a subset of
neocortical plaques were pyroGlu-3 Ab positive. In contrast
to PSAPP mice, aged APP/S1DE9 mice showed strong IR
for general Ab in the leptomeningeal blood vessels, and
plaques in the molecular layer in the cerebellum (Figure 6C)
that often colocalized with pyroGlu-3 Ab IR (Figure 6F).
In summary, the combination of APP and PS1 mutations
resulted in a more aggressive plaque pathology. However,
as shown for APP mutants above, general Ab was deposited377
Frost et alﬁrst, followed by pyroGlu-3 Ab deposition in a subset of
plaques and blood vessels.
Analysis of 3xTg-AD Mice Bearing Mutations in APP,
PS-1, and Tau
In our colony, 3xTg-AD mice possessing the Swedish APP
mutation, PS1M145V, and TauP301L deposited Ab plaques
starting at approximately 14 months of age with advanced
cerebral amyloidosis at approximately 20 months. At the
earliest stages, R1282 IR was observed ﬁrst in the subiculum
and later radiated out to the hippocampal DGm and cortex as
diffuse and focal plaques; however, pyroGlu-3Ab IRwas rare.
However, even at 14months, a small amount of pyroGlu-3Ab
deposition (Supplemental Figure S3J) was observed in
a subset of R1282-positive plaques (Supplemental Figure S3I)
in the subiculum. Subsequent examination of cortical brain
sections from 20- to 28-month-old 3xTg-AD mice (nZ 10)
revealed that pyroGlu-3Ab IR increasedwith age butwas only
observed as intense focal deposits restricted to the subiculum
(Figure 4N) and layer 5 of the cortex in the oldest mouse
examined (28 months), differing from general Ab deposition
that was abundant in diffuse and focal deposits in the hippo-
campus (Figure 4M) and cortex.Discussion
The present study provides a detailed immunohistochemical
analysis of general Ab deposition and N-terminaletruncated
and pyroGlu-3emodiﬁed Ab species. The study aimed to
characterize the sequence and pattern of appearance of
pathology in humans, nonhuman primates, canines, and
mice, based on two highly speciﬁc antibodies, R1282 and
pyroGlu-3 Ab.
Staining in 12 AD cases revealed that pyroGlu-3 Ab was
present in high abundance in focal and diffuse plaques, as
well as in CAA that followed a R1282 staining pattern in all
cases. Complementarily, ﬁndings were observed in cortical
brain tissue from 7 of 10 AC (only those bearing plaques) and
3 of 3 DS patients. Our results in human cases paralleled
several previously published reports. Initial studies by Saido
et al7 demonstrated both immunohistochemically and bio-
chemically that pyroGlu-3 Ab is a major component of senile
plaques in the brains of AD patients and young DS individ-
uals age <30 years. PyroGlu-3 Ab was found in comparable
or greater levels than Ab species, starting at aspartate 1
[Ab1(D)-x]. Therefore, it was concluded that pyroGlu-3 Ab
could play an early and seminal role in AD pathogenesis.
Since then, numerous reports have documented pyroGlu-3
Ab to be present in high abundance in sporadic AD, FAD,
and DS brains,41e43 correlating with disease progression and
severity.10,44,45 This is mainly based on its pivotal toxicity
leading to, eg, the impairment of long-term potentiation
in situ12,17 and neurodegeneration in vivo,21 qualifying
pyroGlu-3 Ab as a target for drug development.378Preclinical studies require suitable animal models
reﬂecting major characteristics of the disease. We found
pyroGlu-3 Ab IR to be present in two models of cerebral
amyloidosis, the Caribbean vervet and beagle canines. Our
laboratory was the ﬁrst to document cerebral Ab accumu-
lation in an age-dependent manner in the Caribbean vervet27
in which Ab deposits ﬁrst appeared in vascular amyloid
as predominantly Ab40-reactive blood vessels. To our
knowledge, we are now the ﬁrst to characterize N-terminally
truncated Ab peptide variants in this model. With aging,
beagles and vervets preferentially begin to deposit pyroGlu-
3 Ab in the vasculature, and later pyroGlu-3 Ab was found
to colocalize in a subset of general Ab-positive plaques. It
became evident that the ﬁxation time has a major impact on
pyroGlu-3 Ab detection. Diffuse deposits comparable to
general Ab IR were only detected in brieﬂy ﬁxed vervet
brain tissue, whereas long-term ﬁxed vervet brains show
pyroGlu-3 Ab IR only in a subset of cortical plaques even in
the oldest monkey tested. This might lead to the underes-
timation of pyroGlu-3 IR also in long-term ﬁxed human AD
cases and has to be taken into consideration for future
immunohistochemical studies on pyroGlu-3 Ab deposition
in human and animal brain tissue.
Despite the desirable usage of animal models showing
sporadic development of AD, such studies are hampered by
the availability, costs, and time until onset of phenotype.
The earliest appearance of pyroGlu-3 Ab was around 17
years of age in vervets and 12 years of age in beagles.
Therefore, mouse models genetically engineered to show
AD-like symptoms within months (rather than years) are the
standard of current research.
Here, we conﬁrmed the deposition of pyroGlu-3 Ab in
a large variety of AD-like tg mouse models. In contrast to the
human phenotype, pyroGlu-3 Ab is found after initial
deposition of general Ab, albeit to a much lesser extent.
Reasons could be a lower activity of murine QC to covert Ab
peptides, as previously suggested by Seifert et al,46 or an
expression pattern of the human APP transgene differing
from the distinct expression pattern of QC in mouse brain.47
The latter might be overcome by coexpression of QC and
APP as, eg, described for human QCeoverexpressing mice
crossed with 5XFAD mice with both transgenes under the
control of the murine Thy-1 promoter. Here, increased levels
of pyroGlu-3 Ab could be detected compared to 5XFAD
alone.48 In addition, it has to be noted that the composition of
Ab peptide species has been shown to be fundamentally
different in mouse models and human AD.49,50
The age of ﬁrst pyroGlu-3 Ab deposition was inﬂuenced
by the extent of genetic manipulation and by the promoter
used in the respective mouse models. PyroGlu-3 Ab was
found at older ages when the Swedish mutation was the only
APP mutation applied in a model (Tg2576, 3xTg-AD).
Comparison of the pathology of APP(Swedish/Indiana)-
expressing mice (J20 and TgCRND8) revealed a much
earlier Ab deposition in TgCRND8 using the Hamster PrP
promoter compared to J20 driving gene expression via theajp.amjpathol.org - The American Journal of Pathology
pGlu-Ab in Humans and Animal ModelsPDGF promoter. Furthermore, combined APP and PS1
mutations caused a more aggressive pathology leading also
to earlier detection of pyroGlu-3 Ab. Here, not only the
proteolytic function of the g-secretase complex might be
altered, but also the PS1-dependent intracellular transport of
APP.51,52 Because FAD PS1 mutations cause a delayed exit
of APP from the trans-Golgi network,51 the time QC has
access to the Ab N-terminus in intracellular compartments is
increased. Thereby, the mildly acid pH in the Golgi network
and in secretory granules would strongly promote glutamate
cyclization,13,18 eventually explaining increased pyroGlu-3
Ab level by PS1 mutations. Similar observations were
made in human FAD patients in whom PS1 mutations led to
a very aggressive phenotype accompanied by massive
pyroGlu-3 Ab deposition.42,53 However, the sequential
appearance of general Ab followed by pyroGlu-3 Ab was
not changed irrespective of the applied FAD mutation in the
mouse models, suggesting that other factors such as genetic
manipulation of the b-secretase cleavage by the Swedish
mutation might also be involved in the pattern observed.
Interestingly, TgSwDI, possessing 2 adjacent FAD mutation
within the Ab sequence, caused a very early deposition of
pyroGlu-3 Ab peptides. Therefore, FAD mutations have
a major impact on pyroGlu-3 Ab deposition in the tested
mouse models.
In summary, our results conﬁrm previous studies which
indicated that pyroGlu-3 Ab is a major species found in
nearly all diffuse and focal Ab deposits, as well as vascular
amyloid in AD, DS, and AC cases, and afﬁrm that pyroGlu-
3 Ab isoforms are disease-relevant species. Treatments
aimed at modulating pyroGlu-3 Ab generation through QC
inhibitors and/or gene expression or through Ab immuno-
therapy by selectively targeting pyroGlu-3 Ab are promising
avenues for the prevention and/or treatment of AD. In
agreement with humans, previously characterized mamma-
lian models used in the study, Caribbean vervets and beagle
canines, contain N-terminally truncated and pyroGlu-
3emodiﬁed Ab species. PyroGlu-3 Ab deposition was
further found to vary signiﬁcantly among different AD-like
Tg mouse models examined in this study for age of onset,
cortical region, and general abundance; however, the same
general paradigm was found among most murine models,
that general Ab precedes pyroGlu-3 Ab deposition and is
usually observed in much lesser quantities, sometimes
correlating the age of onset of behavioral deﬁcits. Future
directions could be aimed at measuring QC expression in
these models to better understand why pyroGlu-3 Ab varied
greatly among each model and whether pyroGlu-3 Ab
deposition correlates with neuron loss and associated gliosis
more than full-length, general Ab.Acknowledgments
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